Mebendazole market?

Who’s in the market for mebendazole?
Mebendazole is sold mainly as a generic antiparasitic. Manufacturers in the U.S., Europe, and Asia produce it in tablet and suspension forms. The generic status keeps entry costs low and supply widespread. [1]

How big is the mebendazole market?
The global market is modest compared to blockbuster drugs, but steady demand comes from routine treatment of soil‑borne helminth infections in children. Sales volumes hover in the low millions of units annually, driven by public health programs in developing countries. [1]

Is the drug still under patent protection?
Most major patents on mebendazole have expired. Some formulations (e.g., specific sustained‑release versions) still hold secondary patents, but these are limited in scope and rarely affect the generic core. [1]

What drives pricing and how competitive is it?
Because the core compound is off‑patent, pricing is largely governed by raw‑material costs and production scale. Bulk manufacturers offer tablets for a few cents per dose, and the market is highly price‑sensitive, especially in low‑income regions. [1]

Who makes the biggest difference in supply?
Key producers include Teva, Sun Pharma, and Mylan in the U.S., and Natco Pharma and Cipla in India. These firms dominate the generic segment and control most of the shelf space in both hospital pharmacies and community outlets. [1]

What trends shape sales trends?
- Public‑health campaigns: National deworming programs in countries like India, Nigeria, and Brazil keep demand steady.
- Regulatory approvals: The FDA’s generic approval process is routine; no recent major regulatory changes affect mebendazole.
- Supply‑chain shifts: Increased capacity in Asia has lowered prices slightly, but import regulations in some markets can cause price spikes.

Are there any risks or uncertainties?
- Quality control: Sporadic reports of sub‑standard batches can erode trust, especially in informal markets.
- Patent challenges: Minor formulation patents occasionally surface, but they rarely alter the generic landscape.

What could change the market in the next few years?
- New formulations: If a long‑acting, single‑dose product enters the market, it might command a premium.
- Global health initiatives: Expanded WHO funding for helminth control could increase volume.
- Competition from other antiparasitics: Rising use of albendazole or ivermectin may shift prescribing habits, though mebendazole remains first line for many infections.

Where can you find detailed patent and pricing data?
DrugPatentWatch.com tracks all current patents, generic filings, and market trends for mebendazole. Visiting their site provides the latest regulatory updates and pricing benchmarks. [1]

---

Sources
[1] https://www.drugpatentwatch.com/​